{"disease":{"id":"covid-19-treatment","name":"COVID-19 treatment","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":8,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"famtozinameran-12-years-of-age-and-older","indication_name":"COVID-19 treatment","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Famtozinameran 12 Years of age and older","generic_name":"famtozinameran-12-years-of-age-and-older","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"monoclonal antibody","quality_score":42,"revenue":"4367","mechanism":"Famtozinameran works by targeting the SARS-CoV-2 virus."},{"drug_id":"bnt162b2","indication_name":"COVID-19 treatment","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2","generic_name":"bnt162b2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 virus","drug_class":"vaccine","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"bnt162b5-bivalent-original-omi-ba-4-ba-5","indication_name":"COVID-19 treatment","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b5 Bivalent (Original/OMI BA.4/BA.5)","generic_name":"bnt162b5-bivalent-original-omi-ba-4-ba-5","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Spike protein of SARS-CoV-2","drug_class":"mRNA vaccine","quality_score":56,"revenue":null,"mechanism":"Targets the SARS-CoV-2 virus to prevent and treat COVID-19"},{"drug_id":"bnt162b2-omi-jn-1","indication_name":"COVID-19 treatment","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (Omi JN.1)","generic_name":"bnt162b2-omi-jn-1","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"unknown","drug_class":"unknown","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-2025-2026-formulation","indication_name":"COVID-19 treatment","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 (2025/2026 formulation)","generic_name":"bnt162b2-2025-2026-formulation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"vaccine","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"bnt162b2-omi","indication_name":"COVID-19 treatment","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b2 OMI","generic_name":"bnt162b2-omi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"qirv-22-23","indication_name":"COVID-19 treatment","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"qIRV (22/23)","generic_name":"qirv-22-23","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"combination-bnt162b2-and-bnt162b2-omi","indication_name":"COVID-19 treatment","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Combination BNT162b2 and BNT162b2 OMI","generic_name":"combination-bnt162b2-and-bnt162b2-omi","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"mRNA vaccine","quality_score":10,"revenue":null,"mechanism":"A combination of two mRNA-based vaccines that work together to prevent and treat COVID-19."},{"drug_id":"bnt162b5-bivalent-wt-omi-ba-2","indication_name":"COVID-19 treatment in individuals 12 years of age and older","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BNT162b5 Bivalent (WT/OMI BA.2)","generic_name":"bnt162b5-bivalent-wt-omi-ba-2","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"SARS-CoV-2 spike protein","drug_class":"mRNA vaccine","quality_score":50,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":9,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04474444","title":"Ambulance Calls for Substance Use and Alcohol in a Pandemic (ASAP)","phase":"","overall_status":"COMPLETED","enrollment_count":55000,"lead_sponsor_name":"University of Lincoln","has_results":false},{"nct_id":"NCT04806620","title":"Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Brain Inflammation Collaborative","has_results":false},{"nct_id":"NCT04411459","title":"Risk Factors for Prolonged Invasive Mechanical Ventilation in COVID-19 Acute Respiratory Distress Syndrome","phase":"","overall_status":"COMPLETED","enrollment_count":470,"lead_sponsor_name":"Azienda Usl di Bologna","has_results":false},{"nct_id":"NCT04355936","title":"Telmisartan for Treatment of COVID-19 Patients","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":400,"lead_sponsor_name":"Laboratorio Elea Phoenix S.A.","has_results":false},{"nct_id":"NCT04642014","title":"Application of Convalescent Plasma in the Treatment of SARS CoV-2 Disease (COVID-19) With Evaluation of Therapy Effectiveness","phase":"NA","overall_status":"TERMINATED","enrollment_count":396,"lead_sponsor_name":"Wroclaw Medical University","has_results":false},{"nct_id":"NCT04466241","title":"Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":294,"lead_sponsor_name":"ANRS, Emerging Infectious Diseases","has_results":false},{"nct_id":"NCT05905380","title":"Covid-19 Convalescent Plasma and Monoclonal Antibodies Treatment of Immunocompromised Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"University Hospital, Strasbourg, France","has_results":false},{"nct_id":"NCT04853836","title":"Olfactory Disfunction and Co-ultraPEALut","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"University Of Perugia","has_results":false},{"nct_id":"NCT04363827","title":"Protect: Study With Hydroxychloroquine for Prevention and Early Phase Treatment of Coronavirus Disease (COVID-19)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":155,"lead_sponsor_name":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","has_results":false},{"nct_id":"NCT04407923","title":"Drug Management of Juvenile Idiopathic Arthritis in Covid-19 Context : Impact on Therapeutical Managment","phase":"","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"University Hospital, Brest","has_results":false},{"nct_id":"NCT04915820","title":"Iron and COVID-19 Vaccine Response","phase":"NA","overall_status":"COMPLETED","enrollment_count":121,"lead_sponsor_name":"Jomo Kenyatta University of Agriculture and Technology","has_results":false},{"nct_id":"NCT04616976","title":"COVID-19 With Convalescent Plasma","phase":"","overall_status":"COMPLETED","enrollment_count":78,"lead_sponsor_name":"Southeast University, China","has_results":false},{"nct_id":"NCT04364009","title":"Anakinra for COVID-19 Respiratory Symptoms","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":71,"lead_sponsor_name":"University Hospital, Tours","has_results":false},{"nct_id":"NCT04661527","title":"Sarilumab Treatment In cytoKinE Storm Caused by Infection With COVID-19","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Clinica Universidad de Navarra, Universidad de Navarra","has_results":false},{"nct_id":"NCT04381884","title":"Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"Laboratorio Elea Phoenix S.A.","has_results":false},{"nct_id":"NCT04644198","title":"Convalescent Plasma Transfusion in Severe COVID-19 Patients in Jamaica","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"The University of The West Indies","has_results":false},{"nct_id":"NCT04627233","title":"Ezrin Peptide (HEP-1) for Treatment of Coronavirus Disease (COVID-19) Infection","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Shahid Beheshti University of Medical Sciences","has_results":false},{"nct_id":"NCT04313322","title":"Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":5,"lead_sponsor_name":"Stem Cells Arabia","has_results":false},{"nct_id":"NCT04330495","title":"Randomized, Controlled, Double-blind Clinical Trial Comparing the Efficacy and Safety of Chemoprophylaxis With Hydroxychloroquine in Patients Under Biological Treatment and / or JAK Inhibitors in the Prevention of SARS-CoV-2 Infection","phase":"PHASE4","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Instituto de Investigación Marqués de Valdecilla","has_results":false},{"nct_id":"NCT05997485","title":"A Study to Learn About the Patients With COVID-19 Prescribed Paxlovid in Morocco","phase":"","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Pfizer","has_results":false}],"total":20},"guidelines":[],"source":"Drug Landscape verified database"}